-  New data include update from the fourth patient treated in the Phase 1/2 trial -  Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response PITTSBURGH , July 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual investor conferences. Details for the events are as follows: Goldman Sachs 42nd Annual

Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4 million PITTSBURGH , May 10, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience,

PITTSBURGH , April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the

PITTSBURGH , April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic

New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosis Company expands rare genetic lung disease pipeline with KB408 for the treatment of alpha-1 antitrypsin deficiency PITTSBURGH , April 19, 2021 (GLOBE NEWSWIRE) -- Krystal

PITTSBURGH , March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete in the pivotal GEM-3 study of B-VEC for dystrophic epidermolysis bullosa (DEB).

PITTSBURGH , March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual conferences. Details for the presentations are as follows: Guggenheim Healthcare Talks:

-  Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections -  Dr. Bhushan Hardas M.D ., MBA appointed President, Jeune, Inc. PITTSBURGH , March 24, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable